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National HIV Testing Day — 
June 27, 2013 
National HIV Testing Day, June 27, promotes the impor-
tance of testing in detecting, treating, and preventing human 
immunodeficiency virus (HIV) infection. HIV testing is the 
essential entry point to a continuum of prevention, health-
care, and social services that improve the quality of life and 
the length of survival for persons with HIV (1). Persons with 
HIV who receive appropriate treatment, monitoring, and 
health care also reduce their chances of transmitting HIV 
to others. CDC recommends that all persons aged 13–64 
years be screened for HIV in health-care settings located in 
areas where the prevalence of undiagnosed HIV infection 
is >0.1%, and that persons with increased risk for HIV be 
retested at least annually (2). 
In April 2013, the U.S. Preventive Services Task Force 
updated its 2005 guidelines on HIV screening, to recom-
mend that clinicians screen all persons aged 15–65 years 
for HIV infection at least once, regardless of their risk; that 
younger adolescents and older adults with increased risk also 
be screened; and that persons with increased risk be screened 
more frequently (3). These updated recommendations are 
based on increasing evidence of the benefits of early antiret-
roviral therapy for HIV-infected persons and its effectiveness 
in preventing HIV transmission. Additional information is 
available at http://www.uspreventiveservicestaskforce.org/
uspstf13/hiv/hivfinalrs.htm#summary, http://www.cdc.gov/
features/hivtesting, and http://www.hivtest.cdc.gov. 
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Detection of Acute HIV Infection in 
Two Evaluations of a New HIV 
Diagnostic Testing Algorithm — 
United States, 2011–2013 
The highly infectious phase of acute human immunodefi-
ciency virus (HIV) infection, defined as the interval between 
the appearance of HIV RNA in plasma and the detection of 
HIV-1–specific antibodies, contributes disproportionately to 
HIV transmission (1). The current HIV diagnostic algorithm 
consists of a repeatedly reactive immunoassay (IA), followed 
by a supplemental test, such as the Western blot (WB) or 
indirect immunofluorescence assay (IFA). Because current 
laboratory IAs detect HIV infection earlier than supplemental 
tests, reactive IA results and negative supplemental test results 
very early in the course of HIV infection have been errone-
ously interpreted as negative (2). To address this problem, 
CDC has been evaluating a new HIV diagnostic algorithm 
(3). This report describes two evaluations of this algorithm. 
An HIV screening program at a Phoenix, Arizona emergency 
department (ED) identified 37 undiagnosed HIV infections 
during July 2011–February 2013. Of these, 12 (32.4%) were 
acute HIV infections. An ongoing HIV testing study in three 
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sites identified 99 cases with reactive IA and negative supple-
mental test results; 55 (55.6%) had acute HIV infection. CDC 
and many health departments recognize that confirmatory 
supplemental tests can give false-negative results early in the 
course of HIV infection. This problem can be resolved by 
testing for HIV RNA after a reactive IA result and negative 
supplemental test result. 
Early HIV IAs used either viral lysate antigens (first genera-
tion) or synthetic peptides and recombinant antigens (second 
generation) and detected only immunoglobulin G (IgG)-class 
antibodies. Most laboratories now use either third-generation 
IAs that detect both immunoglobulin M-class and IgG-class 
antibodies or fourth-generation combination antigen/antibody 
IAs that detect both classes of antibody and also p24 antigen (a 
major core protein of HIV). The p24 antigen can be detected 
early, before antibody appears, allowing the fourth-generation 
IAs to identify some HIV infections in the acute phase. In 
this report, fourth-generation, IA-reactive specimens with a 
negative supplemental test but detectable HIV-1 RNA were 
classified as acute HIV infection. 
The current laboratory diagnostic algorithm for HIV cannot 
detect acute infections and misclassifies approximately 60% of 
HIV-2 infections as HIV-1, based on HIV-1 WB results (4). 
The new diagnostic algorithm evaluated in this study replaces 
the WB with an HIV-1/HIV-2 antibody differentiation assay 
as the supplemental test and includes an RNA test to resolve 
reactive IA with negative supplemental test results (Figure 1). In 
retrospective studies, this algorithm performed better than the 
WB at identifying HIV-antibody–positive persons, detecting 
acute HIV-1 infections, and diagnosing unsuspected HIV-2 
infections (5,6). In this report, data from two evaluations of 
this algorithm are analyzed, one from an HIV testing program 
in Phoenix, Arizona, and the other from an ongoing HIV test-
ing study in three sites. 
In 2011, the Arizona Department of Health Services collabo-
rated with Maricopa Integrated Health Systems* to 1) screen 
all adult ED patients (aged 18–64 years) for HIV who had 
phlebotomy for other reasons as a part of their medical care 
and 2) validate the new algorithm. Specimens were screened 
with a fourth-generation IA (Architect HIV Ag/Ab Combo 
Assay [Architect], Abbott Diagnostics) from July 2011 through 
February 2013. From July 2011 through February 2012, 10 
specimens with repeatedly reactive Architect results were 
tested with both a WB and a Food and Drug Administration 
(FDA)-approved HIV-1/HIV-2 antibody differentiation assay 
(Multispot HIV-1/HIV-2 Rapid Test [Multispot], Bio-Rad 
Laboratories), and from March 2012 through February 2013, 
only with a Multispot (27 specimens). Specimens negative by 
either WB or Multispot were tested for HIV-1 RNA (m2000 
RealTime HIV-1 Quantitative Assay, Abbott Diagnostics). 
The Screening Targeted Populations to Interrupt On-going 
Chains of HIV Transmission with Enhanced Partner 
Notification (STOP) study is evaluating 1) methods to detect 
* Maricopa Integrated Health Systems is a public health-care system in Maricopa County, 
Arizona, that provides hospital- and clinic-based medical care to area residents. 
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acute HIV infection and enhance partner services in New York, 
New York; North Carolina; and San Francisco, California, and 
2) the new diagnostic algorithm. Participants aged >12 years 
who received HIV testing at one of 12 venues from September 
2011 through September 2012 were screened with Architect. 
Repeatedly reactive specimens were tested with Multispot and 
either an HIV-1 WB (Bio-Rad Laboratories) or an in-house 
IFA. Specimens with negative Multispot, WB, or IFA results 
were tested for HIV-1 RNA (either Aptima HIV-1 RNA 
Qualitative Assay [Gen-Probe] or m2000 RealTime HIV-1 
Quantitative Assay). 
Routine HIV screening with Architect in the Phoenix 
ED from July 2011 through February 2013 detected previ-
ously undiagnosed HIV infection in 37 patients (Table). 
The diagnosis of acute HIV infection was established by 
a negative supplemental test but a detectable HIV-1 RNA 
in 12 (32.4%) of these 37 patients. The other 25 HIV 
diagnoses were antibody-positive by Multispot, WB, or both. 
The median HIV-1 viral load among patients with acute 
infection was 3,636,176 copies/mL (interquartile range: 
614,164 to >10,000,000), compared with 27,125 copies/mL 
(9,519–78,084) among patients with established infection. 
In the STOP study, Architect results were repeatedly 
reactive in 654 (1.7%) of 37,876 patients screened from 
September 2011 through September 2012 (Figure 2). 
Multispot was reactive for HIV-1 in 554 (84.7%) patients and 
for both HIV-1 and HIV-2 in one (0.2%). In the 99 (15.1%) 
patients with a negative or HIV-1 indeterminate Multispot 
result, HIV-1 RNA was present in 55 (55.6%), representing 
8.4% of all those with repeatedly reactive Architect results. 
Traditional supplemental tests (either HIV-1 WB or IFA) were 
negative in 37 (67.3%) and indeterminate in seven (12.7%) 
of these 55 Architect-reactive specimens from patients with 
acute HIV-1 infection (Figure 2). 
FIGURE 1. New HIV diagnostic testing algorithm evaluated — United States, 2011–2013 
Fourth-generation HIV-1/2 immunoassay
(-)
Negative for HIV-1 and HIV-2 
antibodies and p24 antigen
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Abbreviation: HIV = human immunodeficiency virus. 
* Additional testing required to rule out dual infection with HIV-1 and HIV-2. 
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Editorial Note 
Improved HIV IAs enhance the ability to detect HIV infection 
earlier, even during the acute phase of infection, when substantial 
HIV transmission occurs. However, specimens with reactive IA 
and negative supplemental test results must undergo further test-
ing to differentiate acute HIV infection from false-positive results. 
This report demonstrates that acute HIV infections detected with 
third- or fourth-generation IAs often are misclassified as HIV-
negative by WB or IFA, potentially leading to adverse clinical 
outcomes for patients and further HIV transmission within the 
community (1). Applying the HIV testing algorithm evaluated in 
this analysis averted missed diagnoses in 32% of the HIV-infected 
patients in the Phoenix ED and 9% of those in the STOP study. 
With FDA’s approval of the Multispot HIV-1/HIV-2 rapid test 
for use as the second test in this algorithm in March 2013, labo-
ratories can adopt this algorithm, which is a recommended option 
in the Clinical and Laboratory Standards Institute’s Criteria for 
Laboratory Testing and Diagnosis of Human Immunodeficiency Virus 
Infection; Approved Guideline (7). The fast turnaround time for 
test results from most third- and fourth-generation IAs (<1 hour) 
and the Multispot rapid test (15 minutes) affords the opportunity 
TABLE. Demographic characteristics, clinical symptoms, and HIV test results of patients who had HIV infection diagnosed in an emergency 
department (ED) using a reactive fourth-generation immunoassay — Phoenix, Arizona, 2011–2013
Patient Sex HIV infection status ED encounter date Differentiation IA Western blot
HIV-1 viral load 
(RNA copies/mL)
Patient 7 Male Acute Oct 2011 Nonreactive Negative >10,000,000
Patient 8 Male Acute Dec 2011 Nonreactive Negative 5,370,318
Patient 11 Male Acute Jan 2012 Nonreactive Inconclusive 1,141,782
Patient 19 Female Acute Apr 2012 Nonreactive ND >10,000,000
Patient 25 Male Acute Jun 2012 Nonreactive ND >10,000,000
Patient 36 Male Acute Sep 2012 Nonreactive ND >10,000,000
Patient 23 Male Acute May 2012 Nonreactive ND 4,357,922
Patient 39 Male Acute Sep 2012 Nonreactive ND 691,343
Patient 57 Male Acute Jan 2013 Nonreactive ND 382,628
Patient 31 Female Acute Jul 2012 Nonreactive ND 309,139
Patient 27 Male Acute Jun 2012 Nonreactive ND 64,163
Patient 3 Male Acute Aug 2011 HIV-1 reactive Negative 2,914,430
Patient 13 Male Established Jan 2012 HIV-1 reactive Positive 86,910
Patient 6 Male Established Oct 2011 HIV-1 reactive Positive 29,476
Patient 5 Female Established Oct 2011 HIV-1 reactive Positive 18,822
Patient 4 Male Established Sep 2011 HIV-1 reactive Positive 15,608
Patient 12 Male Established Jan 2012 HIV-1 reactive Positive 11,209
Patient 2 Male Established Aug 2011 HIV-1 reactive Positive 6,460
Patient 40 Female Established Sep 2012 HIV-1 reactive ND <40 
Patient 56 Male Established Jan 2013 HIV-1 reactive ND 764,498
Patient 32 Male Established Aug 2012 HIV-1 reactive ND 690,951
Patient 16 Male Established Mar 2012 HIV-1 reactive ND 632,488
Patient 59 Male Established Feb 2013 HIV-1 reactive ND 602,878
Patient 42 Male Established Oct 2012 HIV-1 reactive ND 130,248
Patient 28 Female Established Jun 2012 HIV-1 reactive ND 78,084
Patient 58 Male Established Jan 2013 HIV-1 reactive ND 67,808
Patient 61 Male Established Feb 2013 HIV-1 reactive ND 65,105
Patient 29 Male Established Jul 2012 HIV-1 reactive ND 49,873
Patient 24 Male Established Jun 2012 HIV-1 reactive ND 44,816
Patient 48 Female Established Dec 2012 HIV-1 reactive ND 27,125
Patient 41 Male Established Oct 2012 HIV-1 reactive ND 20,692
Patient 38 Male Established Sep 2012 HIV-1 reactive ND 14,925
Patient 30 Male Established Jul 2012 HIV-1 reactive ND 9,519
Patient 22 Female Established May 2012 HIV-1 reactive ND 4,334
Patient 37 Male Established Sep 2012 HIV-1 reactive ND 1,537
Patient 49 Female Established Dec 2012 HIV-1 reactive ND 1,225
Patient 47 Female Established Nov 2012 HIV-1 reactive ND 757
Abbreviations: HIV = human immunodeficiency virus; IA = immunoassay; ND = not done.  
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to deliver same-day definitive test results to the majority of HIV-
infected persons who are antibody-positive. Regardless of which 
supplemental test is used, clinicians and laboratories might want 
to consider further HIV RNA testing for patients whose supple-
mental antibody test results are negative after a reactive third- or 
fourth-generation IA result (8). 
The ED at Maricopa Integrated Health Systems adopted 
routine, opt-out HIV screening consistent with CDC’s 2006 
recommendations (9), using a fourth-generation IA. As a result, 
an additional 37 patients with HIV infection, including 12 with 
acute infection, were identified. Because most currently available 
FDA-approved rapid HIV tests are second-generation format (i.e., 
they detect only IgG-class antibodies), these acute HIV infec-
tions likely would have been missed if point-of-care rapid tests 
had been used for screening. The high percentage of HIV infec-
tions that were acute among these ED patients was unexpected; 
FIGURE 2. Fourth-generation HIV-1/2 immunoassay test results with the new HIV diagnostic testing algorithm — New York, New York; 
San Francisco, California; and North Carolina, September 2011–2012  
Fourth-generation HIV-1/2 immunoassay
N = 37,876
Negative for HIV-1 and HIV-2 
antibodies and p24 antigen
n = 37,222 (98.3%)
Positive for HIV-1 or HIV-2 
antibodies or p24 antigen
n = 654 (1.7%)















HIV-1 (-) [n = 90] or indeterminate [n = 9]
HIV-2 (-)





n = 554 (84.7%)
RNA(+)
Acute HIV-1 infection
n = 55 (55.6%) 
Indirect IFA           (n = 28)
Positive             4* (14.3%)
Indeterminate  2 (7.1%)
Negative         22 (78.6%) 
Western blot       (n = 27)
Positive            7* (26.0%)
Indeterminate 5 (18.1%)
Negative         15 (55.5%) 
Abbreviations: HIV = human immunodeficiency virus; NAT = nucleic acid test; IFA = immunofluorescence assay.  
* Five of the seven Western blot positive results and two of the four IFA positive results occurred with specimens that were HIV-1 indeterminate on the differentiation 
assay. The differentiation assay has four reaction spots, including 1) control, 2) HIV-2 peptide, 3) recombinant HIV-1, and 4) HIV-1 peptide. When used in a diagnostic 
algorithm, both HIV-1 spots (recombinant and peptide) must be reactive for a specimen to be interpreted as positive for HIV-1 antibodies. The presence of only one 
HIV-1 spot is interpreted as indeterminate for HIV-1 antibodies.  
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however, consistent with observations that 50%–90% of persons 
with acute HIV infection develop symptoms that prompt them 
to seek medical care (10), this finding suggests that acute HIV 
infection in persons who seek care for its nonspecific symptoms 
in EDs and other urgent-care venues might go undiagnosed 
unless HIV screening is conducted with fourth-generation HIV 
IAs. Currently, only one RNA assay, the Aptima HIV-1 RNA 
Qualitative Assay, is FDA-approved for HIV diagnosis, but it is 
available in far fewer laboratories than quantitative HIV-1 (viral 
load) RNA assays. To facilitate prompt diagnosis of acute HIV 
infection when faced with discordant screening and supplemental 
antibody test results, clinicians can order a viral load test to dif-
ferentiate acute HIV-1 infection from false-positive IA results. 
The findings in this report are subject to at least two limi-
tations. First, results might not be generalizable to all HIV 
screening programs. Although the goal of the Phoenix ED was 
to screen for HIV as many patients as possible, HIV tests might 
have been ordered on some patients because of clinical suspicion, 
potentially increasing the number of HIV or acute HIV infec-
tions identified. Second, participants in the STOP study were 
a convenience sample of persons at high risk for HIV infection 
attending sexually transmitted infection clinics or community-
based HIV testing programs serving men who have sex with 
men. Therefore, the percentage of HIV-1 infections that were 
acute might be higher than that observed in other populations. 
Third- and fourth-generation IAs are important advances for 
HIV testing that improve the ability to detect HIV infections 
earlier. In the two prospective evaluations described in this 
report, the new diagnostic testing algorithm performed bet-
ter than the current algorithm for identifying HIV infections. 
CDC’s recommendation for a new HIV diagnostic algorithm, 
which will incorporate the findings of this analysis, is under 
development. Clinicians can use the findings from this report 
by remaining vigilant for discordant IA and supplemental 
test results and either ordering an HIV-1 nucleic acid test or 
obtaining follow-up HIV testing (in 2–4 weeks) to accurately 
determine whether HIV infection is present. 
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What is already known on this topic? 
The highly infectious phase of acute human immunodeficiency 
virus (HIV) infection, before the appearance of HIV-1-specific 
antibodies, contributes disproportionately to HIV transmission. 
Improved HIV laboratory immunoassays (IAs) can detect HIV 
infection during this acute phase, when traditional HIV 
supplemental tests (e.g., Western blot) are still negative. Some 
discordant HIV test results (reactive IA and negative supplemen-
tal test) have been erroneously interpreted as HIV-negative. 
What is added by this report? 
Using an HIV testing algorithm that included RNA testing for all 
specimens with reactive IA and negative supplemental 
antibody test results led to the diagnosis of acute HIV infections 
in various HIV testing settings. Using an HIV IA to screen 
patients in an Arizona emergency department identified 37 
undiagnosed HIV infections, of which 32.4% were acute and 
would have been misclassified as HIV-negative by current 
testing practices that rely on antibody tests such as Western 
blot. An ongoing multisite study of a convenience sample of 
persons at high risk identified 99 cases with reactive IA and 
negative supplemental test results; 44.4% were in patients who 
were not infected, but 55.6% had acute HIV infection. These 
acute HIV infections would have been misclassified as HIV-
negative without RNA testing, potentially leading to adverse 
clinical outcomes for patients and further HIV transmission 
within the community. 
What are the implications for public health practice? 
For patients with a reactive HIV IA result and negative supplemental 
antibody test results, additional testing for HIV-1 RNA is necessary to 
identify patients with acute HIV infection. If RNA testing is not 
available, a follow-up IA should be conducted in 2–4 weeks. 
